The use of albuterol/budesonide as reliever therapy to reduce asthma exacerbations.

Anti-inflammatory reliever As-needed Flares Inhaled corticosteroids Nongenomic Reliever Rescue Short-acting beta-2-agonist

Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
03 Feb 2024
Historique:
received: 05 06 2023
revised: 18 12 2023
accepted: 17 01 2024
medline: 6 2 2024
pubmed: 6 2 2024
entrez: 5 2 2024
Statut: aheadofprint

Résumé

Prevention of asthma exacerbations and reduction of systemic corticosteroid burden remain unmet needs in asthma. US asthma guidelines recommend concomitant short-acting β

Identifiants

pubmed: 38316182
pii: S2213-2198(24)00145-4
doi: 10.1016/j.jaip.2024.01.043
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Reynold A Panettieri (RA)

Rutgers Institute for Translational Medicine and Science, The State University of New Jersey, New Brunswick, NJ, United States; Child Health Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States.

Bradley Chipps (B)

Capital Allergy & Respiratory Disease Center, Sacramento, CA, United States. Electronic address: BChipps@CapitalAllergy.com.

Neil Skolnik (N)

Abington Family Medicine, Jenkintown, PA, USA; Department of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States.

Maureen George (M)

Department of Nursing, Columbia University School of Nursing, New York, NY, United States.

Kevin Murphy (K)

Boys Town National Research Hospital, Section of Adult and Pediatric Allergy and Pediatric Pulmonary, Boys Town, NE, United States.

Njira Lugogo (N)

Michigan Medicine, University of Michigan, Ann Arbor, MI, United States.

Classifications MeSH